Rosenthal Benjamin E, Hoteit Maarouf A, Lluri Gentian, Haeffele Christiane, Daugherty Tami, Krasuski Richard A, Serfas John D, de Freitas R Andrew, Porlier Avaliese, Lubert Adam M, Wu Fred M, Valente Anne Marie, Krieger Eric V, Buber Yonatan, Rodriguez Fred H, Gaignard Scott, Saraf Anita, Hindes Morgan, Earing Michael G, Lewis Matthew J, Rosenbaum Marlon S, Zaidi Ali N, Hopkins Kali, Bradley Elisa A, Cedars Ari M, Ko Jong L, Franklin Wayne J, Frederickson Abby, Ginde Salil, Grewal Jasmine, Nyman Annique, Min Jungwon, Schluger Charlotte, Rand Elizabeth, Hilscher Moira, Rychik Jack, Kim Yuli Y
Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Division of Hepatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
JACC Adv. 2025 Apr;4(4):101646. doi: 10.1016/j.jacadv.2025.101646. Epub 2025 Mar 12.
The Fontan operation is a surgical procedure to palliate single ventricle congenital heart disease. Hepatocellular carcinoma (HCC) is a rare complication of Fontan-associated liver disease (FALD).
The authors aim to examine characteristics of individuals with Fontan circulation diagnosed with HCC and to describe tumor characteristics, treatment, and survival outcomes of these patients.
This was a multicenter retrospective case-control study of adults with Fontan circulation between 2005 and 2021. HCC cases were included based on histology or imaging-based diagnosis. Controls were randomly selected in a 3:1 ratio from the center in which the case was derived. Descriptive statistics were used to compare groups and Kaplan-Meier survival analysis was performed.
There were 58 cases of HCC diagnosed at a median age of 31 (IQR: 26-38) years. Diagnosis was made at very early or early stage disease in 68%. Compared to controls, cases had higher prevalence of advanced FALD including varices, ascites, splenomegaly, and decreased platelets. Treatment with curative intent (combined heart-liver transplantation, resection, or ablation) was performed in 41%. Survival at 1 year was 78.9% and highest among those diagnosed at very early or early stage. Over half were undergoing active surveillance at diagnosis, which showed a nonsignificant trend toward higher survival (P = 0.088).
We describe the clinical characteristics, treatment, and survival in patients with FALD-HCC. Results suggest that adults with FALD-HCC diagnosed with early stage disease may have survival benefit. Our findings underscore the importance of HCC screening for early detection in individuals after the Fontan operation.
Fontan手术是一种用于缓解单心室先天性心脏病的外科手术。肝细胞癌(HCC)是Fontan相关肝病(FALD)的一种罕见并发症。
作者旨在研究被诊断为HCC的Fontan循环患者的特征,并描述这些患者的肿瘤特征、治疗及生存结果。
这是一项对2005年至2021年间患有Fontan循环的成年人进行的多中心回顾性病例对照研究。HCC病例基于组织学或影像学诊断纳入。对照组从病例来源的中心按3:1的比例随机选取。采用描述性统计比较各组,并进行Kaplan-Meier生存分析。
共诊断出58例HCC,中位年龄为31岁(四分位间距:26 - 38岁)。68%的病例在疾病极早期或早期被诊断。与对照组相比,病例中晚期FALD的患病率更高,包括静脉曲张、腹水、脾肿大和血小板减少。41%的患者接受了根治性治疗(联合心肝移植、切除或消融)。1年生存率为78.9%,在极早期或早期被诊断的患者中最高。超过一半的患者在诊断时接受了积极监测,这显示出生存率有升高的非显著趋势(P = 0.088)。
我们描述了FALD-HCC患者的临床特征、治疗和生存情况。结果表明,被诊断为早期疾病的FALD-HCC成年患者可能有生存获益。我们的研究结果强调了在Fontan手术后对个体进行HCC筛查以早期发现的重要性。